Login to Your Account



Regado Launches Phase III Trial Testing First-in-Class Clotbuster

By Catherine Shaffer
Staff Writer

Tuesday, September 17, 2013
Regado Biosciences Inc., of Basking Ridge, N.J., enrolled its first patient in the Phase III REGULATE-PCI trial of its antithrombotic drug, REG1, in patients undergoing percutaneous coronary intervention (PCI). The trial will compare REG1 to Angiomax (bivalirudin, The Medicines Co.).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription